Kuwatsuka, Yachiyo
Tomizawa, Daisuke
Kihara, Rika
Nagata, Yasunobu
Shiba, Norio
Iijima-Yamashita, Yuka
Shimada, Akira
Deguchi, Takao
Miyachi, Hayato
Tawa, Akio
Taga, Takashi
Kinoshita, Akitoshi
Nakayama, Hideki
Kiyokawa, Nobutaka
Saito, Akiko Moriya
Koh, Katsuyoshi
Goto, Hiroaki
Kosaka, Yoshiyuki
Asou, Norio
Ohtake, Shigeki
Miyawaki, Shuichi
Miyazaki, Yasushi
Sakura, Toru
Ozawa, Yukiyasu
Usui, Noriko
Kanamori, Heiwa
Ito, Yoshikazu
Imai, Kiyotoshi
Suehiro, Youko
Kobayashi, Shinichi
Kitamura, Kunio
Sakaida, Emiko
Ogawa, Seishi
Naoe, Tomoki
Hayashi, Yasuhide
Horibe, Keizo
Manabe, Atsushi
Mizutani, Shuki
Adachi, Souichi
Kiyoi, Hitoshi
Funding for this research was provided by:
Japan Agency for Medical Research and Development
National Cancer Center Research and Development Fund (26-A-24)
Article History
Received: 7 June 2017
Revised: 28 September 2017
Accepted: 2 October 2017
First Online: 12 October 2017
Compliance with ethical standards
:
: Dr. Miyachi reports grant from AMED and personal fees for consulting from BML. Inc. Dr. Saito reports grants from Ministry of Health, Labor and Welfare, grants from AMED, during the conduct of the study. Dr. Asou reports grants from Nippon Shinyaku Co., Ltd., grants and personal fees from Kyowa Hakko Kirin Co., Ltd., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants from Astellas Pharma Inc., grants and personal fees from Sumitomo Dainippon Pharma Co., Ltd., grants from Toyama Chemical Co., Ltd., grants and personal fees from Asahi Kasei Pharma Co., Ltd., personal fees from Boehringer Ingelheim Japan Inc., personal fees from Bristol-Myers Squibb Co., Ltd., personal fees from Nippon Kayaku Co., Ltd., personal fees from Yakult Honsha Co., Ltd., outside the submitted work. Dr. Miyazaki reports grants from AMED, grants from National Cancer Center Research and Development Fund, during the conduct of the study; grants and personal fees from Chugai Pharma, grants and personal fees from Kyowa Hakko Kirin Co., Ltd., grants and personal fees from Astellas Pharma, personal fees from Dainippon Sumitomo, personal fees from Celgene Japan, grants and personal fees from Novartis Japan, outside the submitted work. Dr. Usui reports grants from AMED, during the conduct of the study; personal fees from Astellas Pharma. Inc., grants and personal fees from Bristol-Myers Squibb Co., Ltd., grants and personal fees from Celgene Co., Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from CIMIC Co., Ltd., personal fees from Eli Lilly Japan, grants and personal fees from Fujimoto Pharmaceutical Co., Ltd., personal fees from Huya Bioscience International, personal fees from Janssen Pharmaceutical Co., Ltd., personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from Nippon Boehringer-Ingelheim Co., Ltd., grants from Nippon Shinyaku Pharmaceutical Co., Ltd., grants from Novartis Pharma, grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants and personal fees from Pfizer Co., Ltd., personal fees from SymBio Pharmaceuticals Co., Ltd., grants and personal fees from Sysmex Co., Ltd., personal fees from Takeda Bio Development Center Ltd., personal fees from Zenyaku Kogyo Co., Ltd., outside the submitted work. Dr. Kobayashi reports grants from Kyowa Kirin, grants from Shionogi, grants from Zenyaku Kogyo, grants from Taiho Pharma, grants from Chugai Pharmaceutical, grants from Asahi Kasei Pharma, grants from Astellas, grants from Eisai, grants from Ono Pharmaceutical, grants from Toyama Chemical, grants from Takeda Pharmaceutical, grants from MSD, outside the submitted work. Dr. Ogawa reports grants and personal fees from KAN Research Institute, Inc., other from Asahi Genomics Co., Ltd., grants from Nippon Shinyaku Co., Ltd., grants from Takeda Pharmaceutical Co., Ltd., outside the submitted work. Dr. Naoe reports grants from Fujifilm Corporation, outside the submitted work; In addition, Dr. Naoe has a patent null pending. Dr. Kiyoi reports grants from AMED, grants from National Cancer Center Research and Development Fund, during the conduct of the study; grants from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Bristol-Myers Squibb, grants from Kyowa Hakko Kirin Co., Ltd., grants from Zenyaku Kogyo Co., Ltd., grants from FUJIFILM Corporation, grants from Nippon Boehringer Ingelheim Co., Ltd., grants and personal fees from Astellas Pharma Inc., grants from Celgene Corporation, personal fees from Daiichi Sankyo Co., Ltd., grants and personal fees from Pfizer Japan Inc, grants from Nippon Shinyaku Co., Ltd., grants from Eisai Co., Ltd., grants from Takeda Pharmaceutical Co., Ltd., grants from Ono Pharmaceutical Co., Ltd., grants from Japan Blood Products Organization, outside the submitted work. The other authors declare no competing financial interests.